Study drug was not longer available in our country.

The purpose of this study is to determine whether nasal administration of salmon calcitonin is effective and safe in the treatment of symptoms and signs of primary fibromyalgia.

Fibromyalgia is a common, chronic musculoskeletal disorder that is characterized by widespread pain and tenderness. Fibromyalgia occurs in around 2% of the US general population, is more common in women and is associated with substantial morbidity and disability. Treatment of fibromyalgia has been disappointing; roughly one-third of patients have had a clinically important therapeutic response to medications or no-medicinal treatment, event with the newest drugs reported in the literature. Pathophysiology of fibromyalgia is unknown, but abnormalities in central neurotransmission might play a role. Some studies have shown that salmon calcitonin increases peripheral and central levels of endorphins. Increasing endorphins levels may decrease pain. Then, it is feasible that nasal administered salmon calcitonin may decrease several of the symptoms and signs of patients suffering fibromyalgia.

Inclusion Criteria:

• Female patients between 18 and 50 years
• Fibromyalgia diagnosis (ACR criteria)
• Must be able to apply the nasal medication
• Must be able to comply with study visits
• Must be able to understand informed consent
• Must be able to answer self-administered questionnaires
• Must have an active disease(VAS > 60mm)

Exclusion Criteria:

• Comorbid conditions (i.e. hypothyroidism, diabetes mellitus, etc.)
• Any disturbance in the nasal tissue
• Use of concomitant opioid analgesics
• Contraindication to use salmon calcitonin (allergy, hypocalcemia, hypophosphatemia)
• Other rheumatic diseases
• Diagnosis of major depressive disorder